super range and superquick
On Xiaomi's 15th anniversary, CEO Lei Jun introduced the company's first electric SUV, the YU7. This follows the release of the SU7 sedan. It will launch in China officially in July this year when pricing will also be announced.
What is it?
The YU7 is a mid-to-large electric SUV built on the company's Modena platform. It is 5.0m in length, 2m in width, and 1608mm in height, with a 3m wheelbase. YU7 will be available in nine exterior colours, including a green shade inspired by Colombian emeralds. Weight varies between 2140 kg and 2460 kg depending on the model. Wheel choices include 19- and 20-inch sizes.
Special features include inward-folding electric door handles with ambient lighting and Ultra Wideband support for smartphone-based keyless entry and trunk access.
Inside, the 'zero gravity' front seats are Nappa leather lined, with massage function. Rear passengers benefit from electrically adjustable seats and a 6.68-inch touch control screen for climate, music, and navigation functions.
Widescreen
The dashboard has a 1.1m-wide 'HyperVision' set-up that consists of three Mini LED screens with high-level resolution. The system integrates driving data, media, blind-spot imaging, and customizable widgets. YU7 includes a 4-in-1 domain controller that integrates cabin, assisted driving, vehicle control, and communications systems. Underpinning it is a Snapdragon 8 Gen 3 chip set, ensuring fast boot-up in 1.35sec and over-the-air updates in 15 minutes.
Three models
YU7 RWD: This has a single 235kW rear motor offering 528Nm of torque and a sprint time to 100 of 5.9sec.
YU7 Pro AWD: Dual motors produce system output of 365kW and 690Nm for a 0–100km/h time of 4.27sec.
YU7 Max AWD: The top model makes with 508kW and 866Nm, for a claimed sprint time of 3.23sec. It uses a 220kW front motor and 295kW rear unit.
All examples run on Xiaomi's 800V silicon carbide high-voltage platform. Under maximum charging speeds, the YU7 can add up to 620km of range in 15 minutes.
Battery configurations
RWD: 96.3kWh LFP battery, 835km of range
Pro AWD: 96.3kWh LFP battery, 770km of range
Max AWD: 101.7kWh NCM battery, 760km of range
Safety first
The vehicle structure includes a 2200 MPa ultra-high-strength steel integrated roll cage, an aluminium die-cast front frame, and a steel-aluminium hybrid body referred to as an 'armour cage.' The battery pack incorporates a reinforced shell with a 'bullet-resistant' coating. The mind boggles. Xiaomi says that over 50 passive safety tests have been conducted. The A- and B-pillars have also been structurally enhanced.
YU7 uses Xiaomi's in-house developed end-to-end assisted driving system. Standard on all variants are Lidar sensors and Nvidia Drive AGX Thor (700 TOPS), paired with 4D mmWave radar and ALD-coated anti-glare cameras.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Guardian
13 minutes ago
- South Wales Guardian
Ross Kemp says he owes EastEnders ‘a great debt' and refuses to rule out return
The 60-year-old returned to EastEnders as Grant Mitchell after almost 10 years away during its 40th anniversary celebrations earlier this year, as his character returned to Albert Square to help his brother Phil with his mental health problems. Grant recently left Walford again for his home in Portugal. Asked on ITV's Loose Women whether he would return to the role again, Kemp said: 'You just don't know, do you? You don't know what's in the minds of the people who work on it. 'I've also (always) known that without it, I wouldn't have had the career that I've had, I've always owed it a great debt and it was very good to me, and hopefully I was good to it, and why not keep it that way? 'I've always believed that you should leave doors swinging rather than shut them.' Kemp, who went on to produce a number of documentaries since first leaving EastEnders in 1999 including Ross Kemp On Gangs, Ross Kemp In Afghanistan and Ross Kemp: Extreme World, said he enjoyed returning to the soap. He explained: 'It was so wonderful to jump into Grant's leather jacket again, which I can still get in. 'It's a family, it's an ongoing thing, and I'm talking about the past, and they're really busy doing their own thing, I just parachute in, and I exit generally by the tube station. 'But they've got to be welcoming, because it's like a high-speed train, you've got to jump on it at the right time or you miss it. 'So luckily, Steve McFadden (who plays Phil), and Paul Bradley (who plays Nigel Bates), and Letitia (Dean, who plays Sharon Watts) opened the door for me, and it was like going back home, and it was great.' Kemp began on the soap in 1990, and his previous appearance prior to his 2025 return, in 2016, marked his on-screen mother Dame Barbara Windsor's final episode as Peggy Mitchell. The actor currently hosts the BBC gameshow Bridge Of Lies, which challenges contestants to cross a digital bridge by choosing a true statement over a set of wrong ones.
South Wales Guardian
13 minutes ago
- South Wales Guardian
One-time therapy may be ‘transformative option' for treating deadly skin cancer
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer. It could become a 'transformative option' for patients with this type of skin cancer, experts said. Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year. Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body. The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust. At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects. The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer. Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients. 'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.' Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024. Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma. Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively. Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.' Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care. 'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.' Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden. She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier. 'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said. 'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon. 'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.' Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
Yahoo
13 minutes ago
- Yahoo
Golden Odds Acquires ThaiScore.com, Launches Predictive Sports Platform in Thailand
Golden Odds has officially entered the Thai market through the acquisition of New York, NY, June 02, 2025 (GLOBE NEWSWIRE) -- Golden Odds, the global predictive intelligence brand revolutionizing sports betting content, has officially entered the Thai market through the acquisition of — a localized football-focused platform known for real-time score updates and fan engagement. Golden Odds With this strategic move, Golden Odds introduces AI-powered, expert-verified match predictions to Thai fans via ThaiScore's trusted platform and community channels. 'Thailand is one of the most engaged sports betting markets in Southeast Asia. Through ThaiScore, we're bringing a new level of clarity, excitement, and confidence to how fans follow and forecast matches,' said Andrew Goldie, Founder & CEO of Golden Odds. Key Highlights: Prediction Engine Launch: 40+ data points per match, now live under /previews on Real-time, mobile-friendly livescore service covering local and international fixtures. Localization First: All content is Thai-language, mobile-optimized, and written by Thai football experts Community Rollout: Official LINE and Telegram channels launching for direct fan engagement Monetization Model: Dual focus on affiliate marketing and performance-driven display ads ThaiScore will continue to operate under its own name and domain, now clearly 'powered by Golden Odds,' maintaining its unique voice while gaining access to global tech, content frameworks, and strategic infrastructure. Golden Odds is also actively expanding in Korea and Indonesia as part of its 2025 Asia roadmap. ### About Golden Odds Golden Odds is a global sports predictive intelligence network, offering AI-powered, expert-validated real-time match predictions in multiple languages. The platform empowers sports fans to make smarter, faster, and more confident decisions through dynamic, human-readable insights. Media Contact: press@ Alan Smith +44 7452 018 755 DISCLAIMER: The contents of this press release are for informational purposes only. You should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this press release constitutes a consultation or a solicitation for investment or the purchase or sale of any financial asset. Any investment decision should be made after consulting with a professional about your specific circumstances. The information provided in this press release does not constitute advice or investment opinion, and it should not be relied upon as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any reader's particular investment objectives, financial situations, or needs. Readers should not consider it as financial advice and should consult with their financial advisor before making any investment decisions. Neither the distribution company nor its partners are responsible for any decision made on the basis of this press release. Any decision based on this press release should be made after consulting with a professional. The source of this press release, Golden Odds, must be contacted for any queries. Sign in to access your portfolio
